About US
Dedicated to AAT therapeutics for Respiratory diseases
Of high medical need with global societal impact
AATec Medical is a biotech company developing a product platform based on recombinant alpha-1 antitrypsin (AAT) for the treatment of airway inflammatory diseases, viral and bacterial respiratory infections and rare diseases. We have successfully demonstrated proof-of-principle in several indications and are preparing for a proof-of-concept clinical trial with inhaled AAT in respiratory applications.
We were founded by a seasoned interdisciplinary team with long-standing experience in clinical research, biopharmaceutical drug development and product industrialization. The team provides a comprehensive biomedical and industrial skill set based on long term expertise to drive the research, product development, and clinical testing of our product pipeline.
OUR LEADERSHIP
Dr. Rüdiger Jankowsky
CEO and Co-founderRüdiger has more than 20 years of experience in the biotech industry and is a seasoned leader with comprehensive expertise in product development and regulatory approval. He served as CEO for several life science start-ups, built interdisciplinary expert organizations for R&D and biotech licensing and was instrumental in the development, regulatory approval, and partnering of multiple biopharmaceuticals.
PD Dr. Manfred Stangl
CSO and and Co-founderManfred is Director Physician of the renal and pancreas transplant unit at the University Clinic of Munich, with decades of experience in medical and biopharmaceutical research. He previously founded Apceth Biopharma, a biotech company for the manufacturing of stem cells which was acquired by Hitachi in 2018.
Dr. Michael Strassmair
CMO and Co-founderMichael is Director Physician at the Manu Sana clinic in Starnberg/Munich and has many years of experience in clinical studies. He is working on the strategic determination of target indications of our products and is preparing clinical development strategies in conjunction with regulatory activities.
ADVISORY BOARD
Dr. Karsten Ottenberg
Chair of the Advisory Board and Co-founderKarsten is the former CEO and Executive of multinational corporates including the BSH Home Appliances Group, Giesecke & Devrient and Philips Semiconductors (now NXP). Karsten brings his global experience in strategy, innovation, industrial scaling and business management to our team. He also acts as a mentor for impact scale-ups on global platforms such as Endeavor and The Unreasonable Group.
Willem Bulthuis
Member of the Advisory Board and Co-founderWillem Bulthuis is dedicated since 2015 to supporting global venturing ecosystems, as co-founder, board member and advisor at ventures, as business angel, as venture partner at VC Funds. His focus is on deeptech and sustainability topics like transport, energy, recycling, construction, and health. Willem brings over 30 years of executive experience at global high-tech corporations like Philips Electronics, NXP Semiconductors, G&D and Secunet, as Global Sales Executive, CTO and Member of the Board. He lived in Europe and Silicon Valley and is based in Munich since 2010.
Prof. Burkhard Sträter
Member of the Advisory BoardBurkhard is specialized in regulatory affairs and pharmaceutical law. He founded his lawfirm in 1987, advising pharmaceutical companies and medical device manufacturers on clinical development, national and European marketing authorization and pharmacovigilance for drugs and medical devices. As a leading European expert in his field, Burkhard became Head of the Board of Studies and Examinations at the University of Bonn, Germany in 2008. He is continuously providing advanced management training for the pharmaceutical industry and healthcare institutions.
SCIENTIFIC ADVISORY BOARD
Prof. Dr. Ulrike Protzer
Member of the Scientific Advisory BoardProf. Dr. Ulrike Protzer, Director of the Institute of Virology at the Technical University of Munich and at Helmholtz Munich, Germany, is an internationally recognized expert in virus research and viral diseases. With her deep-rooted expertise in virology, she has been at the forefront of researching various viral infections and their impact on human health.
Prof. Dr. Jan Münch
Member of the Scientific Advisory BoardProf. Jan Münch, Director of the Institute of Molecular Virology at the University Hospital Medical Center in Ulm, Germany, is a leading expert in antiviral research. Amongst numerous highly ranked scientific publications, his team demonstrated effective inhibition of coronavirus entry into host cells by AAT, as published in Nature Communications.
Dr. Gerhard Scheuch
Member of the Scientific Advisory BoardDr. Gerhard Scheuch, CEO of GS BIO-INHALATION GmbH, is a seasoned biophysicist with an extensive background in aerosol medicine and pulmonary drug delivery. He has been instrumental in the development of various products for inhalation therapy and was appointed as a scientific advisor for the EMA. He previously served as a board member and president of the International Society for Aerosols in Medicine (ISAM). Dr. Scheuch co-founded several companies, including Inamed (acquired by Nuvsian in 2019), Activaero (acquired by Vectura in 2014), and Ventaleon.
Prof. Dr. Claus Franz Vogelmeier
Member of the Scientific Advisory BoardClaus Vogelmeier, Professor of Medicine and Head of the Department for Pulmonary Medicine at the Philipps-University of Marburg, Germany, is a leading expert in clinical research regarding lung diseases. He has a long-standing scientific and clinical interest in obstructive lung diseases with topics ranging from pathogenetic aspects to novel diagnostic methods and clinical studies. He has published numerous papers in high ranking journals.